Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
Dose-ranging efficacy of sitagliptin, a dipeptidyl peptidase-4 inhibitor, in Japanese patients with type 2 diabetes mellitus
复制标题
DOI：
10.1507/endocrj.k09e-272
复制
发表时间：
2010-05-20
影响因子：
2
通讯作者：
Amatruda, John
中科院分区：
文献类型：
--
作者：
Iwamoto, Yasuhiko;Taniguchi, Tadaaki;Amatruda, John
西格列汀是一种口服、强效、高选择性、每日一次的DPP-4抑制剂，适用于治疗2型糖尿病（T2DM）。评估每日一次西格列汀25,50,100和200mg在日本T2DM患者中的剂量范围有效性和安全性/耐受性。在这项随机、双盲、安慰剂对照的研究中，363名血糖控制不足的日本患者(HbA(1c)=6.5-10%；台塑
Sitagliptin is an oral, potent, highly selective, once-daily DPP-4 inhibitor indicated for the treatment of type 2 diabetes mellitus (T2DM). To assess the dose-ranging efficacy and safety/tolerability profile of once-daily sitagliptin 25, 50, 100, and 200 mg in Japanese patients with T2DM. In this randomized, double-blind, placebo-controlled study, 363 Japanese patients with inadequate glycemic control (HbA(1c)=6.5-10%; FPG